Stonebridge Capital Advisors’s Charles River Laboratories CRL Stock Holding History

Stonebridge Capital Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3	Closed	-$588	–	350
2023 Q3	$588	Sell	3 -23	-88%	-$4.72K	﹤0.01%	877
2023 Q2	$5.47K	Buy	26 +23	+767%	+$4.58K	﹤0.01%	708
2023 Q1	$605	Hold	3	–	–	﹤0.01%	887
2022 Q4	$654	Sell	3 -31	-91%	-$6.77K	﹤0.01%	889
2022 Q3	$7K	Buy	34 +9	+36%	+$1.94K	﹤0.01%	631
2022 Q2	$5K	Hold	25	–	–	﹤0.01%	700
2022 Q1	$7K	Hold	25	–	–	﹤0.01%	718
2021 Q4	$9K	Hold	25	–	–	﹤0.01%	651
2021 Q3	$10K	Buy	+25	New	+$10.4K	﹤0.01%	619

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Stonebridge Capital Advisors's CRL Position: Q4 2023 in Review

Stonebridge Capital Advisors sold out of Charles River Laboratories (CRL) in Q4 2023, closing a stake of 3 shares — an estimated $588 sold.

Stonebridge Capital Advisors first reported a position in CRL in Q3 2021 and held it in 9 quarters. The position peaked at $10K in Q3 2021. 634 funds tracked by Wall St. Rank hold CRL as of Q4 2023.

Stonebridge Capital Advisors reported no remaining Charles River Laboratories position as of Q4 2023 after selling out during the quarter.
Stonebridge Capital Advisors sold 3 Charles River Laboratories shares in Q4 2023, an estimated $588.
Stonebridge Capital Advisors first reported a position in Charles River Laboratories in Q3 2021 and held it in 9 quarters.
Stonebridge Capital Advisors's Charles River Laboratories position peaked at $10K in Q3 2021.
634 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.